FluxMPS™ MCDB 131 Medium: 1X Liquid

FluxMPS™ MCDB 131 Medium: 1X Liquid

FluxMPS™ DCP-M1311X is an MPS-grade, ultra-filtered MCDB 131 formulation engineered for serum-free or low-protein culture of Human Microvascular Endothelial Cells (HMVEC) and related cell models on organ-on-a-chip (OoC) and microphysiological system (MPS) platforms. Processed through a Quadruple-stage filtration system (0.1 µm ×2 + 0.04 µm ×2), it delivers approximately 5× lower particulate counts than conventional 0.22 µm–filtered media — ensuring trace elements are delivered particle-free and endotoxin is below TLR4 activation threshold. Formulation: [+] Low Glucose (1000 mg/L), [+] L-Glutamine, [+] Sodium Pyruvate, [+] Sodium Bicarbonate, [+] Trace Elements.

• Trace element formulation — zinc, copper, selenium, manganese for metalloenzyme support and antioxidant activity in serum-free culture
• Optimized for: Human Microvascular Endothelial Cells (HMVEC), HUVEC, HAEC, primary endothelial cells
• 0.04 µm final nano-filtration — trace elements delivered as dissolved ions, not particulate aggregates
• Quadruple-stage filtration: 0.1 µm pre-I → 0.04 µm pre-II → 0.1 µm sterile-I → 0.04 µm final polish
• Endotoxin < 0.05 EU/mL — below TLR4 activation threshold for sensitive primary cell models
• Ultrapure Type 1 water (18.2 MΩ·cm), ISO 13485:2016 QMS, ISO Class 5 fill

Engineered where standard media fails

MCDB media formulated for primary cells contain trace element salts that can form subvisible particulate aggregates when filtered at 0.22 µm under typical manufacturing conditions. These aggregates clog microfluidic channels, disrupt trace metal bioavailability, and activate innate immune signaling in sensitive primary cell models. FluxMPS™ eliminates these failure modes with four-stage sub-0.04 µm filtration and < 0.05 EU/mL endotoxin.

Quadruple-stage filtration system

Four serial filtration stages reaching a final 0.04 µm polish under ISO Class 5 aseptic conditions — delivering sub-mycoplasma purity and particle-free trace element delivery unavailable from conventional 0.22 µm filtered MCDB media.

1. 1

   0.1 µm Pre-filtration I — Large Particulate & Aggregate Removal

   Removes large aggregates including trace metal salt precipitates; protects downstream 0.04 µm membranes and chip geometries from fouling.

2. 2

   0.04 µm Pre-filtration II — Mycoplasma Barrier

   Retains mycoplasma (0.1–0.3 µm) and residual fine particulates — absent from standard 0.22 µm filtration.

3. 3

   0.1 µm Sterile-filtration I — Second-pass Redundancy

   Second-pass sterility redundancy; no breakthrough from Stage 1.

4. 4

   0.04 µm Sterile-filtration II — Final Polish

   Ultimate sub-mycoplasma polish; ISO Class 5 aseptic fill & finish.

Specialized cell models & OoC applications

FluxMPS™ DCP-M1311X was formulated specifically for Human Microvascular Endothelial Cells (HMVEC), HUVEC, HAEC, primary endothelial cells in low-protein or serum-free conditions. The 0.04 µm filtered trace element matrix enables safe use in microfluidic chip architectures where conventional MCDB media would cause trace metal particulate fouling.

Automated Bioreactors & Robotics

Optional 0.01 µm (10 nm) ultra-filtered variant available for automated bioreactor perfusion where trace metal salt nanoparticulates in standard MCDB media cause valve fouling.

• Trace Metal Nanoparticulate Removal: 10 nm filtration removes sub-0.04 µm metal salt colloids invisible to standard QC
• Valve & Sensor Protection: Eliminates micro-fouling from trace element aggregates in automated systems
• Extended Perfusion Stability: Consistent trace element delivery over weeks-long primary cell culture

Inquiry Required: Contact support@diagnocine.com for the 0.01 µm variant.

Analytical release specifications

Every lot released against the full specification matrix. CoA: support@diagnocine.com.

Full composition (mg/L)

MCDB 131: 53 ingredients verified per lot with CAS numbers for full raw-material traceability. Contains trace elements for metalloenzyme support and antioxidant activity.

Manufacturing & compliance

Every FluxMPS™ product manufactured and released under a rigorous multi-layer quality system, with particular attention to trace element dissolution and particulate removal during MCDB formulation.

How DCP-M1311X compares

FluxMPS™ DCP-M1311X vs. conventional 0.22 µm–filtered MCDB 131 formulations.

Frequently asked questions

Common questions about FluxMPS™ DCP-M1311X MCDB 131.

Supporting literature

Key publications supporting MCDB 131 for Human Microvascular Endothelial Cells (HMVEC) culture and organ-on-a-chip applications.

1. Ham RG, McKeehan WL. Media and growth requirements. Methods Enzymol. 1979;58:44–93. doi:10.1016/S0076-6879(79)58127-6
2. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760–772. doi:10.1038/nbt.2989
3. Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328:1662–1668. doi:10.1126/science.1188302
4. Novak R, et al. Robotic fluidic coupling and interrogation of multiple vascularized organ chips. Nat Biomed Eng. 2020;4:407–420. doi:10.1038/s41551-019-0497-x
5. Campisi M, et al. 3D self-organized microvascular model of the human blood-brain barrier. Biomaterials. 2018;180:117–129. doi:10.1016/j.biomaterials.2018.07.014
6. Jang KJ, et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol. 2013;5:1119–1129. doi:10.1039/c3ib40049b
7. Schimek K, et al. Integrating biological vasculature into a multi-organ-chip microsystem. Lab Chip. 2013;13:3588–3598. doi:10.1039/c3lc50217a
8. Luni C, et al. High-efficiency cellular reprogramming with microfluidics. Nat Methods. 2016;13:446–452. doi:10.1038/nmeth.3832
9. Sung JH, et al. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip. 2013;13:1201–1212. doi:10.1039/c3lc41017j